Core Viewpoint - The resignation of the chairman and key personnel of Ruian Gene Technology Co., Ltd. raises concerns about the company's leadership and ongoing operations, but the company asserts that daily operations and technical research remain normal [1][3]. Group 1: Leadership Changes - Chairman Xiong Hui has resigned from her positions as chairman, director, general manager, and core technical personnel due to personal reasons, but will continue to hold other roles within the company [1][3]. - Xiong Hui's husband, Gao Shangxian, will take over the position of chairman following her resignation [3]. Group 2: Legal Issues - In July 2024, Xiong Hui and other key personnel were placed under residential surveillance due to suspected illegal operations, with some later facing criminal detention [5]. - By October 2024, the charges against Xiong Hui and others were changed to fraud, and by December 2024, they were formally arrested, with the case entering the prosecution phase [5]. Group 3: Company Overview - Ruian Gene was established in 2012 and specializes in the research, production, and sales of in vitro diagnostic products, including testing instruments and reagents [5]. - The company provides precise genetic and antigen testing for patients with blood diseases, solid tumors, and infectious diseases [5].

Core Viewpoint - The resignation of Xiong Hui, the chairman of Ruian Gene, raises concerns about the company's leadership and ongoing operations, although she remains the actual controller of the company [3][4]. Group 1: Leadership Changes - Xiong Hui has resigned from her positions as chairman, director, general manager, and core technical personnel due to personal reasons, but will continue to hold other roles within the company [1][3]. - Gao Shangxian, Xiong Hui's husband, will take over the chairman position following her resignation [3]. Group 2: Legal Issues - Xiong Hui and other key personnel have been subjected to criminal detention for alleged fraud, with the case currently under review by the prosecution [2][6]. - The legal troubles may be linked to a fraud case involving AstraZeneca, where there were allegations of falsifying genetic testing reports for insurance reimbursement [6][7]. Group 3: Company Background - Ruian Gene, established in 2012, specializes in the research, production, and sales of in vitro diagnostic products, focusing on precision testing for blood diseases, solid tumors, and infectious diseases [4]. - The actual controllers of the company include Xiong Hui, Gao Shangxian, Xiong Jun, and Gao Ze, collectively holding 30.62% of the company's shares [4]. Group 4: Financial Performance - In the first half of 2025, Ruian Gene reported a revenue of 105 million yuan, a decrease of 22.29% year-on-year, and a net profit attributable to shareholders of 3.55 million yuan, down 61.46% year-on-year [7].